📢We have a new member in the club: The 𝗜𝗻𝘀𝘁𝗶𝘁𝘂𝘁𝗲 𝗳𝗼𝗿 𝗗𝗶𝗮𝗯𝗲𝘁𝗲𝘀 𝗮𝗻𝗱 𝗢𝗿𝗴𝗮𝗻𝗼𝗶𝗱 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 (𝗜𝗗𝗢𝗧), led by Matthias Hebrok, was founded in September 2022! We are very much looking forward to working together! 🙌 #WelcomeToTheFamily

🎉We are pleased to announce that Hebrok Lab has started the next chapter of its scientific journey TU München & Helmholtz Diabetes Center (HDC) . Stay tuned for exciting news about mammalian pancreas organogenesis and pancreatic diseases!

Diabetes Germany reunion at FC Bayern game in Munich. ⁦Heiko Lickert⁩, Matthias Hebrok. ⁦Matthias Tschöp⁩ and Stephan Herzig with season tickets.

Pancreatic organoids👨‍🔬 👉This is what Matthias Hebrok, director of our new Institute for #Diabetes & #Organoid Technology focuses on. 💡His goal: Finding new paths for novel therapies for #diabetes & #pancreaticCancer. 👉Read about his spirit & ideas: 🔗t1p.de/0dkxh

We are hiring! One admin and one technician position are available in our lab! Please find more detailed information: #adminposition portal.mytum.de/jobs/sonstige/… #technicianposition portal.mytum.de/jobs/sonstige/… #hiring #TUM #technischeassistenz #secretary

I would like to thank the Heinz Nixdorf Stiftung for their generous and ground-breaking support of an endowed TUM professorship for AI-supported organoid development at the Center for Organoid Systems (COS).

I would like to thank the “Bavarian Ministry of Science“ for awarding me the “Bavarian Distinguished Professorship” and the TUM and Helmholtz Munich for their support. It is a great honor for me and my lab to receive this special award.

Publication alert 🚨: Our paper about Sox9 regulating alternative splicing in beta cells is out in Nature Communications! nature.com/articles/s4146… Thanks to Sapna and all co-authors for this tremendous work! #splicing #betacells #diabetes #stemcells #Perseverance

For the first time in more than a decade, the FDA has approved a new first-line treatment for patients with metastatic #pancreaticcancer, called NALIRIFOX. After a clinical trial showed a positive survival benefit, the combination chemotherapy called NALIRIFOX is now approved

Job alert 📢! We are looking for an enthusiastic postdoc with experience in beta cell biology and/or human stem cell differentiation to join our team. More information here: tinyurl.com/ye2e2dz5

Thankful for this exciting opportunity to speak with members of the German Parliament about our research on stem cell based therapies for diabetes.

Exciting to hear about the great science of our CPA colleagues at the Summer Party. Congrats to our postdocs Kai Duan and Jia Mei for giving excellent speed talk and poster presentations. #Science #StemCells #NextGen #Organoids #diabetes #Cancer

Thrilled to share one of our biggest discoveries: “Inceptor binds to and directs insulin towards lysosomal degradation in beta cells”. doi.org/10.1038/s42255… A tremendous collaborative effort led by Johanna Siehler, Sára Bileková and other members of the Heiko Lickert lab.

Publication alert 🚨 Happy to share our work on engineered suppressor cells for localized immunosuppression, e.g. for T1D, out in Science: science.org/doi/10.1126/sc… Fantastic collaboration with the teams of Wendell Lim and Audrey Parent at UCSF Cell Design Institute @UCSF Audrey Parent Diabetes Center at UCSF

Paper alert!! 🥳😁 I am over the moon to share the biggest (and best) part of my #phd in Maximilian Reichert lab at TU München #phdvoice #phdchat A work that started almost 5 years ago, is finally out in Nature Biomedical Engineering Let’s break it down together 1/ 🧵 nature.com/articles/s4155…

Congratulations to our senior postdoc and all-around beta cell expert Hasna Maachi for being accepted into the prestigious Helmholtz Munich High Potentials Program (HPP)! linkedin.com/posts/helmholt… helmholtz-munich.de/en/high-potent…